Tag Archives: Merck

Cold Cuts: Merck Layoffs Loom

By Reid Paul | Published: January 7, 2010
Image via Wikipedia It is not just cold outside these days, as Merck & Co. makes some cold hard decisions. Following on the heels of its now closed acquisition of Schering-Plough, Merck is making significant job cuts across its operations. Some 16,000 jobs are expected to be eliminated in total as a result of the merger. According [...]
Posted in Strategy | Also tagged , , , | Leave a comment

Merck, Schering-Plough Merger Boosts Global Profile, but Questions Linger

By Andrew Sheivachman | Published: November 5, 2009
Image via Wikipedia After Merck & Co. officially announced its $41.1 billion merger with Schering-Plough yesterday, CEO Richard Clark made it clear his company is still looking to expand through further acquisitions and mergers. According to the Wall Street Journal’s Health Blog: Clark told us today that the newly combined company  is “actively looking” for biotechs to [...]
Posted in Strategy | Also tagged , , , , , , | 2 Comments

Merck/Schering-Plough Merger Highlights (Update 1)

By George Koroneos | Published: March 9, 2009
Merck and Schering-Plough’s CEOs are giving a run down of the benefits of the $41.1 billion merger, announced this morning, in a conference call with investors. Here are some of the highlights: • Total price of the sale will be $41.1 billion or $23.6 per Schering share. • This deal is structured as a reverse merger with [...]
Posted in Deals, Strategy | Also tagged , , , , , | 4 Comments

Schering-Plough to Merge with Merck for $41.1 Billion

By George Koroneos | Published: March 9, 2009
Merck’s Richard T. Clark Image via Wikipedia Merck announced, a little over an hour ago, that it had signed an agreement with Schering-Plough’s board of directors to merge the two companies under the Merck name. The stock and cash transaction is worth over $41 billion with Schering shareholders receiving $10.50 per share in cash and 0.5767 of a [...]
Posted in Deals | Also tagged , , , , | Leave a comment

Pharma Layoffs Continue

By Cassandra Blohowiak | Published: March 4, 2009
It’s been another tough few weeks for pharma employees as four more companies handed out pink slips in an effort to trim bottom lines. Elan cut 14 percent of its global work force last Wednesday as a part of an ongoing strategic review process. The company announced that it would postpone biologics manufacturing, redesign R&D in [...]
Posted in Strategy | Also tagged , , , , , | 1 Comment